drugset / Trial / NCT00950274

Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery

NCT00950274 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

In spite of the fact that the post-myocardial infarction survival rate has improved with recent medical advances, reduced heart function attributed to irreversible loss of viable cardiomyocytes is still a major clinical problem. The aim of the current study is to determine whether intramyocardial injection of autologous CD133+ bone marrow stem cells yields a functional benefit in addition to coronary artery bypass graft (CABG) surgery in patients with chronic ischemic coronary artery disease.

Timeline

Start
2009-07
Primary completion
2016-03
Completion
2017-09

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment stopped due to slow recruitment”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator CD133+ autologous bone marrow stem cell Cell therapy 5 ml Other